6 March 2024
PureTech Health plc
PDMR Notifications
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases, announces that awards of restricted share units ("RSUs") granted by PureTech on 21 July 2021 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested on 4 March 2024 following satisfaction of performance conditions measured over the three year period to 31 December 2023.
Each PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 5 March 2024. The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 200 pence, being the average closing price of the Company's shares over the three-trading day period immediately preceding the settlement, and the exchange rate used to calculate the cash payment and amount of share settlement was £1: $1.26.
The Company's total issued ordinary share capital is 289,468,159 shares after the share issuance to the PDMRs, 19,259,058 shares of which are held in treasury by the Company.
PDMR Notification
The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||||||
| a) | Name | Daphne Zohar Bharatt Chowrira Eric Elenko | ||||||||||||
| 2 | Reason for the notification | |||||||||||||
| a) | Position/status | Daphne Zohar - Chief Executive OfficerBharatt Chowrira - President and Chief Business, Financial and Operating OfficerEric Elenko - Chief Innovation and Strategy Officer | ||||||||||||
| b) | Initial notification/Amendment | Initial Notification | ||||||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
| a) | Name | PureTech Health plc | ||||||||||||
| b) | LEI | 213800LVPDNO2Z9T9I39 | ||||||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
| a) | Description of the financial instrument, type of instrument |
| ||||||||||||
| b) | Nature of the transaction | Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes. | ||||||||||||
| c) | Price(s) and volume(s) |
| ||||||||||||
| d) | Aggregated information
|
| ||||||||||||
| e) | Date of the transaction | 5 March 2024 | ||||||||||||
| f) | Place of the transaction | London Stock Exchange (XLON) | ||||||||||||
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 28 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both US FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.